Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc (Hons), Jason W. Callahan, BAppSc (Hons), Nicholas Hardcastle, PhD, Lisa Crawford, BAppSc, Phillip Antippa, MBBS, FRACS, Gavin Wright, MBBS, FRACS, Michael P. MacManus, MD, MRCP, FRANZCR, Rodney J. Hicks, MD, MBBS, FRACP, Tomas Kron, PhD, David L. Ball, MD, MBBS, FRANZCR Journal of Thoracic Oncology Volume 10, Issue 7, Pages 1112-1115 (July 2015) DOI: 10.1097/JTO.0000000000000555 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions
FIGURE 1 The 4D positron emission tomography (PET)/computed tomography (CT) acquisition (above) and 3D PET/CT acquisition (below) in a patient with a lower lobe tumor, demonstrating CT images (left), PET images (middle), and coregistered PET/CT images (right). Journal of Thoracic Oncology 2015 10, 1112-1115DOI: (10.1097/JTO.0000000000000555) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions